文献速递骨质疏松与代谢性骨病

罗莫佐单抗治疗骨质疏松患者的早期临床疗效、安全性及骨标志物选择:一项6个月研究

Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
PubMed 文献 · Osteoporos Int · 2020-09-26

本研究对185例接受罗莫佐单抗210 mg每4周皮下注射治疗6个月的骨质疏松患者进行前后对照研究,观察新发椎体骨折、安全性、脊柱与全髋骨密度及骨代谢标志物。治疗4至6个月后脊柱和全髋骨密度较基线分别变化6.34%和1.53%,无新发骨折及包括心血管疾病在内的致死性不良事件。基线脊柱骨密度低、TRACP-5b高和iP1NP高的患者疗效尤其明显。

要点

  • 罗莫佐单抗治疗6个月无新发骨折,无包括心血管疾病在内的致死性不良事件。
  • 治疗4至6个月后脊柱和全髋骨密度较基线分别变化6.34%和1.53%。
  • 基线脊柱骨密度低、TRACP-5b高和iP1NP高的患者疗效尤其明显。

核心结论

  • 罗莫佐单抗可有效预防骨折并有助于提高脊柱骨密度,使用相对安全,对基线脊柱骨密度低、TRACP-5b高和iP1NP高的患者尤其有效。

研究设计与样本

  • 前后对照研究,纳入185例接受罗莫佐单抗治疗的骨质疏松患者,治疗6个月。
  • 罗莫佐单抗以210 mg每4周一次皮下注射给药。
  • 治疗前及治疗4至6个月后评估骨密度,治疗前及治疗1、3、6个月后行血清分析。

主要发现

  • 治疗期间无新发骨折,无包括心血管疾病在内的致死性不良事件。
  • 治疗4至6个月后脊柱和全髋骨密度较基线分别变化6.34%和1.53%。
  • TRACP-5b和iP1NP在罗莫佐单抗治疗期间有显著变化(p < 0.05)。
  • 治疗1个月后TRACP-5b和iP1NP较基线的百分比变化与治疗4至6个月后骨密度较基线的百分比变化相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Our 6-month study showed the usefulness of romosozumab for preventing fractures and its safety. It was effective in patients with low baseline spine BMD, high TRACP-5b, and high iP1NP. Percent change from baseline of TRACP-5b and iP1NP after 1 month correlated with that from baseline of BMD after four to 6-month treatment. INTRODUCTION: Romosozumab appeared as a new osteoporosis medication in Japan in 2019. It is an anti-sclerostin antibody which increases bone formation and suppresses bone resorption. In this study, we analyzed the actual clinical effects, adverse effects, and the optimal way to evaluate the treatment. METHODS: Romosozumab was administered as subcutaneous injection of 210 mg once every 4 weeks. We conducted pre-post study in 185 patients treated for 6 months. We focused on the incidence of new vertebral fractures, safety, bone mineral density (BMD) at the spine and total hip, and bone metabolism markers. We evaluated BMD before romosozumab treatment and after 4 to 6 months and performed the serum analysis before romosozumab treatment, after 1, 3, and 6 months. RESULTS: There was no new fracture during treatment, and there was no fatal adverse event including cardiovascular disease. Since percent changes from baseline of the spine and total hip BMD were 6.34% and 1.53% after 4- to 6-month treatment, the treatment was effective for spine osteoporosis. Tartrate-resistant acid phosphatase 5b (TRACP-5b) and intact type I procollagen N-terminal propeptide (iP1NP) had significant changes during romosozumab treatment (p < 0.05). Percent change from baseline of TRACP-5b and iP1NP after 1 month correlated with percent change from baseline of BMD after 4 to 6 months of treatment. CONCLUSION: Romosozumab is effective in preventing fractures and useful for increasing the spine BMD. Also, romosozumab is relatively safe to use. It is especially effective in patients with low baseline spine BMD, high TRACP-5b, and high iP1NP.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Tominaga A, Wada K, Kato Y, et al. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int. 2020. PMID: 32979066. doi:10.1007/s00198-020-05639-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。